Advertisement

Topics

FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with ...

07:06 EDT 1 Aug 2017 | BioMedReports - Blog
Relapsed and refractory AML is a debilitating disease with a significant unmet medical need2

Read more...

Original Article: FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with ...

NEXT ARTICLE

More From BioPortfolio on "FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with ..."

Quick Search
Advertisement